Blood-Based Biomarkers of Neuroinflammation in Alzheimer's Disease: A Central Role for Periphery?

Overview

Journal Diagnostics (Basel)

Specialty Radiology

Date 2021 Sep 28

PMID 34573867

Citations 17

Authors

Federica Angiulli

Elisa Conti

Chiara Paola Zoia

Fulvio Da Re

Ildebrando Appollonio

Carlo Ferrarese

Lucio Tremolizzo

Affiliations

Soon will be listed here.

Abstract

Neuroinflammation represents a central feature in the development of Alzheimer's disease (AD). The resident innate immune cells of the brain are the principal players in neuroinflammation, and their activation leads to a defensive response aimed at promoting β-amyloid (Aβ) clearance. However, it is now widely accepted that the peripheral immune system-by virtue of a dysfunctional blood-brain barrier (BBB)-is involved in the pathogenesis and progression of AD; microglial and astrocytic activation leads to the release of chemokines able to recruit peripheral immune cells into the central nervous system (CNS); at the same time, cytokines released by peripheral cells are able to cross the BBB and act upon glial cells, modifying their phenotype. To successfully fight this neurodegenerative disorder, accurate and sensitive biomarkers are required to be used for implementing an early diagnosis, monitoring the disease progression and treatment effectiveness. Interestingly, as a result of the bidirectional communication between the brain and the periphery, the blood compartment ends up reflecting several pathological changes occurring in the AD brain and can represent an accessible source for such biomarkers. In this review, we provide an overview on some of the most promising peripheral biomarkers of neuroinflammation, discussing their pathogenic role in AD.

Citing Articles

Evidence Suggesting Prolonged Neuroinflammation in a Subset of Children after Moderate/Severe TBI: A UCLA RAPBI Study.

McCabe C, Dennis E, Lindsey H, Babikian T, Bickart K, Giza C medRxiv. 2025; .

PMID: 39974138 PMC: 11838928. DOI: 10.1101/2025.01.20.25320782.

Blood levels of cytokines highlight the role of inflammation in Alzheimer's disease.

Campanelli L, Galeano P, Prestia F, Cuesta C, Dalmasso M, Flores-Lopez M Heliyon. 2025; 11(2):e41725.

PMID: 39872450 PMC: 11770505. DOI: 10.1016/j.heliyon.2025.e41725.

ASC specks as a single-molecule fluid biomarker of inflammation in neurodegenerative diseases.

Lobanova E, Zhang Y, Emin D, Brelstaff J, Kahanawita L, Malpetti M Nat Commun. 2024; 15(1):9690.

PMID: 39528447 PMC: 11555386. DOI: 10.1038/s41467-024-53547-0.

Association between Inflammatory and Metabolic Biomarkers and Common Mental Disorders among Adults: 2015 Health Survey of São Paulo, SP, Brazil.

Ferreira L, Fisberg R, Sarti F, Rogero M Metabolites. 2024; 14(10).

PMID: 39452916 PMC: 11509269. DOI: 10.3390/metabo14100535.

Alzheimer's Disease: Exploring the Landscape of Cognitive Decline.

Tenchov R, Sasso J, Zhou Q ACS Chem Neurosci. 2024; 15(21):3800-3827.

PMID: 39392435 PMC: 11587518. DOI: 10.1021/acschemneuro.4c00339.

References

Fiala M, Zhang L, Gan X, Sherry B, Taub D, Graves M . Amyloid-beta induces chemokine secretion and monocyte migration across a human blood--brain barrier model. Mol Med. 1998; 4(7):480-9. PMC: 2230332. View

Ashutosh , Kou W, Cotter R, Borgmann K, Wu L, Persidsky R . CXCL8 protects human neurons from amyloid-β-induced neurotoxicity: relevance to Alzheimer's disease. Biochem Biophys Res Commun. 2011; 412(4):565-71. PMC: 3236067. DOI: 10.1016/j.bbrc.2011.07.127. View

Marsh S, Abud E, Lakatos A, Karimzadeh A, Yeung S, Davtyan H . The adaptive immune system restrains Alzheimer's disease pathogenesis by modulating microglial function. Proc Natl Acad Sci U S A. 2016; 113(9):E1316-25. PMC: 4780638. DOI: 10.1073/pnas.1525466113. View

Kiyota T, Gendelman H, Weir R, Higgins E, Zhang G, Jain M . CCL2 affects β-amyloidosis and progressive neurocognitive dysfunction in a mouse model of Alzheimer's disease. Neurobiol Aging. 2012; 34(4):1060-8. PMC: 4011558. DOI: 10.1016/j.neurobiolaging.2012.08.009. View

Sofroniew M, Vinters H . Astrocytes: biology and pathology. Acta Neuropathol. 2009; 119(1):7-35. PMC: 2799634. DOI: 10.1007/s00401-009-0619-8. View

Arango Duque G, Descoteaux A . Macrophage cytokines: involvement in immunity and infectious diseases. Front Immunol. 2014; 5:491. PMC: 4188125. DOI: 10.3389/fimmu.2014.00491. View

Park C, Carboni E, Wood P, Gee K . Characterization of peripheral benzodiazepine type sites in a cultured murine BV-2 microglial cell line. Glia. 1996; 16(1):65-70. DOI: 10.1002/(SICI)1098-1136(199601)16:1<65::AID-GLIA7>3.0.CO;2-A. View

Liu D, Cao B, Zhao Y, Huang H, McIntyre R, Rosenblat J . Soluble TREM2 changes during the clinical course of Alzheimer's disease: A meta-analysis. Neurosci Lett. 2018; 686:10-16. DOI: 10.1016/j.neulet.2018.08.038. View

Jack Jr C, Bennett D, Blennow K, Carrillo M, Dunn B, Budd Haeberlein S . NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease. Alzheimers Dement. 2018; 14(4):535-562. PMC: 5958625. DOI: 10.1016/j.jalz.2018.02.018. View

10.

Galimberti D, Fenoglio C, Lovati C, Venturelli E, Guidi I, Corra B . Serum MCP-1 levels are increased in mild cognitive impairment and mild Alzheimer's disease. Neurobiol Aging. 2005; 27(12):1763-8. DOI: 10.1016/j.neurobiolaging.2005.10.007. View

11.

Orre M, Kamphuis W, Osborn L, Jansen A, Kooijman L, Bossers K . Isolation of glia from Alzheimer's mice reveals inflammation and dysfunction. Neurobiol Aging. 2014; 35(12):2746-2760. DOI: 10.1016/j.neurobiolaging.2014.06.004. View

12.

Xia M, Qin S, McNamara M, MacKay C, Hyman B . Interleukin-8 receptor B immunoreactivity in brain and neuritic plaques of Alzheimer's disease. Am J Pathol. 1997; 150(4):1267-74. PMC: 1858175. View

13.

Montagne A, Barnes S, Sweeney M, Halliday M, Sagare A, Zhao Z . Blood-brain barrier breakdown in the aging human hippocampus. Neuron. 2015; 85(2):296-302. PMC: 4350773. DOI: 10.1016/j.neuron.2014.12.032. View

14.

Kim T, Lim H, Lee J, Kim D, Park S, Lee C . Changes in the levels of plasma soluble fractalkine in patients with mild cognitive impairment and Alzheimer's disease. Neurosci Lett. 2008; 436(2):196-200. DOI: 10.1016/j.neulet.2008.03.019. View

15.

Alvarez A, Cacabelos R, Sanpedro C, Garcia-Fantini M, Aleixandre M . Serum TNF-alpha levels are increased and correlate negatively with free IGF-I in Alzheimer disease. Neurobiol Aging. 2006; 28(4):533-6. DOI: 10.1016/j.neurobiolaging.2006.02.012. View

16.

Hoogland I, Houbolt C, van Westerloo D, van Gool W, van de Beek D . Systemic inflammation and microglial activation: systematic review of animal experiments. J Neuroinflammation. 2015; 12:114. PMC: 4470063. DOI: 10.1186/s12974-015-0332-6. View

17.

Malaguarnera L, Motta M, Di Rosa M, Anzaldi M, Malaguarnera M . Interleukin-18 and transforming growth factor-beta 1 plasma levels in Alzheimer's disease and vascular dementia. Neuropathology. 2006; 26(4):307-12. DOI: 10.1111/j.1440-1789.2006.00701.x. View

18.

Lananna B, McKee C, King M, Del-Aguila J, Dimitry J, Farias F . /YKL-40 is controlled by the astrocyte circadian clock and regulates neuroinflammation and Alzheimer's disease pathogenesis. Sci Transl Med. 2020; 12(574). PMC: 7808313. DOI: 10.1126/scitranslmed.aax3519. View

19.

Norden D, Godbout J . Review: microglia of the aged brain: primed to be activated and resistant to regulation. Neuropathol Appl Neurobiol. 2012; 39(1):19-34. PMC: 3553257. DOI: 10.1111/j.1365-2990.2012.01306.x. View

20.

Lunardelli M, Crupi R, Siracusa R, Cocuzza G, Cordaro M, Martini E . Co-ultraPEALut: Role in Preclinical and Clinical Delirium Manifestations. CNS Neurol Disord Drug Targets. 2019; 18(7):530-554. DOI: 10.2174/1871527318666190617162041. View